the Food and Drug Administration (FDA) to issue a series of "black box" warnings in the 1990s, leading to the restriction or withdrawal of several prokinetic agents due to cardiovascular safety concerns.
In this review, we detail the basic cellular and molecular mechanisms of drug-induced arrhythmias, namely drug-induced long QT syndrome (DI-LQTS); examine the cardiovascular safety profiles of common classes of gastroprokinetic agents; and highlight current and future strategies that can be utilized to mitigate the risk of druginduced pro-arrhythmia associated with these and other QT interval prolonging medications.
| Mechanisms of drug-induced arrhythmias
Many common heart rhythms such as bradycardia and first-degree heart block can be triggered by pharmacologic agents. However, the realization that drugs used commonly in the treatment of a wide range of unrelated clinical conditions can prolong the QT interval and confer risk of TdP-associated sudden death has made DI-LQTS one of the most clinically relevant and widely discussed drug-induced cardiac arrhythmias. [3] [4] [5] [6] [7] Like many clinical entities, DI-LQTS is multifactorial in origin and tends to surface in the presence of multiple patient and drug-specific risk factors, some of which are modifiable (electrolyte abnormalities, co-administration of other QT-prolonging agents, and drug accumulation due to renal/hepatic impairment or inhibition of cytochrome P450 metabolism), while others are not modifiable (female sex, underlying genetic disposition, structural heart disease, and diabetes, for example; Table 1 ). [8] [9] [10] We summarize below current knowledge of the cellular and molecular mechanisms that underlie DI-LQTS.
| Cardiac repolarization: cellular mechanisms and clinical correlates
The coordinated opening and closing of the cardiac sodium (Na 
. 11 Whenever at least some ventricular action potentials are prolonged, ventricular repolarization time increases as reflected by QT prolongation on the surface electrocardiogram (ECG) ( Figure 1C ).
As the QT interval is a heart-rate-dependent metric calculation of the heart-rate-corrected QT interval (QTc) from either lead II or V 5 of the 12-lead ECG, using a formula such as Bazett's is required before any intra-individual or inter-individual QT interval comparisons can be made. Current joint American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines define a prolonged
QTc as >450 ms in males and >460 ms in females. 12 However, at least 5%-10% of individuals within the general population have a QTc A "pro-QTc" score ≥4 based on risk factors similar to those listed above was an independent predictor of mortality in patients with QT interval prolongation. 8 Unfortunately, the predictive value of these risk factors in patients with normal or borderline QT intervals has not been assessed.
Key Points
• Many prokinetic agents carry a small but increased risk of drug-induced arrhythmia.
• This review details the mechanisms underlying drug-induced QT prolongation, examines the cardiovascular safety profiles of common prokinetic agent classes, and highlights strategies to mitigate the risk of arrhythmia associated with prokinetic agents.
• Until prokinetic agents with more favorable cardiovascular safety profiles are developed and approved for worldwide use, awareness of patient-and drug-specific risk factors can help mitigate the risk of drug-induced arrhythmia.
>460 ms on screening ECG. 13 Therefore, sex-specific, 99.5th percentile QTc values (>470 ms for males and >480 ms for females) are often used as a cut-off to identify those who would benefit from screening for congenital LQTS. In practice, a baseline QTc value ≥500 ms is considered definitely abnormal, and a rapid drug-induced QTc increase (ΔQTc) >60 ms is used commonly as a marker of the type of exaggerated QTc response that leads to increased TdP risk in DI-LQTS. 14 Regardless of the ultimate QTc-prolonging mechanism (acquired/ drug-induced vs congenital), significant lengthening of the cardiac action potential duration is accompanied by frequent early after depolarizations (EADs) mediated by reactivation of L-type Ca 2+ and sodium-calcium exchange currents during phases 2 and 3 of the cardiac action potential (ie, ill-timed premature ventricular beats, Figure 1B ). In turn, triggered activity from focal EADs coupled with electrical heterogeneity in adjacent regions of myocardium likely generates the conditions needed for unstable reentry and the initiation,
propagation, and maintenance of TdP or "twisting of the points," the hallmark, multi-focal, self-sustaining form of polymorphic ventricular tachycardia associated with LQTS ( Figure 1D ). to the withdrawal of terfenadine, a non-sedating antihistamine in 1997. 5, 17, 18 This was followed by a wave of cardiovascular safetyrelated drug withdrawals, including the prokinetic agent cisapride. 19, 20 This series of high profile drug withdrawals raised awareness of DI-LQTS among healthcare providers, pharmaceutical companies, and regulatory bodies and brought renewed research interest in elucidating the pathophysiologic mechanisms underlying DI-LQTS.
For the vast majority of drugs causing DI-LQTS and DI-TdP, the underlying pathogenic mechanism was linked, at least initially, to intracellular drug-induced blockade of the rapidly activating component of the phase 3 delayed rectifier K + current (I Kr ) conducted by hERG/K v 11.1 K + channels (Table 2) . 21, 22 In turn, I Kr blockade prolongs the cardiac action potential duration/QTc and generates the electrical conditions required for EAD-mediated TdP ( Figure 1A-D) . The exquisite sensitivity of hERG/K v 11.1 to drug-induced blockade has been attributed to an unusually wide internal cavity or "mouth" located below the narrow K + selectivity filter-containing pore that permits access to a large number of drugs. In addition, the presence of multiple aromatic groups within this inner cavity facilitates the formation of covalent π-bonds with these so-called hERG-blocking drugs. 23 However, some drugs (eg, fluoxetine and pentamidine) 24 28 demonstrated that moxifloxacin had no effect on PI3K/I NaL . It is unknown whether this observation is limited to moxifloxacin or represents a fluoroquinolone class effect. d Both erythromycin and azithromycin have been shown to increase peak I Na and/or I NaL . However, the effect of clarithromycin on PI3K/I NaL remains unknown.
T A B L E 2 Representative pharmacologic agents (listed by therapeutic class) associated with drug-induced long QT syndrome/torsades de pointes (functional GI/motility drugs are shown in bold)
( Figure 1A) . 27 This mechanism applies to erythromycin (Table 2) . 28 Interestingly, drugs that also inhibit PI3K/increase I NaL current appear to be more torsadogenic than those that only cause hERG/ K v 11.1 blockade. 28 Thus, in vitro markers of DI-LQTS risk, most notably the hERG/K v 11.1 half maximal inhibitory concentration (IC 50 ) which is used currently in drug screening during the development process, may underestimate the true DI-LQTS/TdP liability of some pharmacologic agents.
| Pharmacodynamics and safety profiles of prokinetic agents
Under an ongoing contract with the FDA's "Safe Use Initiative," the independent non-profit Arizona Center 
| Dopamine receptor antagonists
Dopamine is a critical neurotransmitter whose release from enteric At present, metoclopramide is the only FDA-approved drug for gastroparesis and is considered first-line pharmacologic therapy for this purpose. 34 However, the use of metoclopramide and other centrally acting D 2 antagonists is complicated by an ~1% risk of extrapyramidal side effects, which range in severity from mild akathisia to irreversible tardive dyskinesia, when used chronically and/or at high doses. 35 Since the FDA affixed a tardive dyskinesia-related "black box"
warning in 2009, the use of metoclopramide in the management gastroparesis has declined precipitously. 35, 36 In contrast, domperidone, which does not readily cross the bloodbrain barrier, is not associated with extrapyramidal side effects. 37 Due to cardiovascular safety concerns ( 
| Motilin receptor agonists
Motilin is a GI hormone synthesized and secreted by specialized mucosal endocrine cells in the epithelia of the duodenum and gastric antrum during the interdigestive (fasting) state that exists between meals. 50 The release and binding of motilin to motilin receptors are believed to facilitate acetylcholine release from gut cholinergic motor neurons, thereby indirectly enhancing the amplitude of cholinergically mediated upper GI smooth-muscle contractions during phase III of the migrating motor complex (MMC). 51, 52 These motilin-mediated bursts of forceful high amplitude contractions during phase III of the MMC help clear the upper GI tract of undigested material, prevent bacterial overgrowth, and stimulate the sensation of hunger. 53, 54 Some macrolide antibiotics, namely azithromycin and erythromycin, also function as non-selective motilin receptor agonists that can induce phase III of the MMC and accelerate gastric emptying. [55] [56] [57] In view of these actions, erythromycin and, to a lesser extent, azithromycin are used off-label to rapidly remove gastric contents prior to intubation or endoscopy, facilitate enteral feeding, and treat acutely individuals with a range of GI motility issues such as gastroparesis and chronic intestinal pseudo-obstruction. 54 Clinically, the chronic use of erythromycin as a gastroprokinetic, even at a dose (125 mg before meals) well below that used for antibiotic purposes (250 to 500 mg every 6 to 12 hours), is hindered by the phenomenon of tachyphylaxis and growing concerns surrounding bacterial resistance and the need for appropriate antibiotic stewardship. 58 In addition, erythromycin has mild-to-moderate affinity for hERG/K v 11.1, 59 markedly increases I NaL via PI3K inhibition, 28 and, in rare cases, causes exaggerated QTc response, TdP, and SCD (Table 3) .
Of note, the majority of erythromycin-related TdP/SCD events has occurred during rapid intravenous administration and/or in hosts with ≥1
additional patient-specific DI-LQTS risk factor (Table 1) . 60 As erythromycin is predominantly metabolized by CYP3A family members, 61 it is not surprising that the small, but increased risk of SCD associated with oral erythromycin administration appears to be driven, in large part, by co-administration of strong CYP3A inhibitors such as azole antifungal agents (eg, fluconazole), protease inhibitors (eg, ritonavir), and non-dihydropyridine calcium channel blockers (eg, diltiazem). 62 Thus, the rare TdP/SCD adverse events linked definitively to oral erythromycin likely represent similar multifactorial "perfect storms" to those described previously for domperidone.
Azithromycin, which has very weak affinity for hERG/K v 11.1 (Table 3) 63 and is not metabolized by CYP3A family members, was long considered to be a safe alternative to QTc-prolonging macrolides such as erythromycin. Thus, the discovery that azithromycin stimulates GI motility via activation of motilin receptors led to speculation that azithromycin might represent the preferred macrolide gastroprokinetic agent due to its favorable cardiovascular safety profile. However, a growing body of epidemiologic and electrophysiological evidence, [64] [65] [66] [67] including the recent description of a azithromycin-induced arrhythmogenic state with a pattern of altered ion currents similar to those seen with PI3K inhibition ( Figure 1A) , 67 supports the notion that azithromycin is also potentially torsadogenic, particularly in those individuals with ≥1 additional cardiovascular/QTc risk factor (Table 1) .
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T A B L E 3 Comparison of potency of hERG/Kv11.1 (I Kr ) blockade and number of serious postmarketing adverse events for gastroprokinetic agents with active or prior regulatory approval Cisapride (risk of TdP) and tegaserod (risk of myocardial infarction) were withdrawn from the United States and International market. c With chronic use, both azithromycin and erythromycin, may be associated with increase late sodium current (I NaL ), potentially related to inhibition of cardiac PI3K signaling. Thus, the potency of hERG/Kv11.1 block likely underestimates the true risk of DI-LQTS/TdP associated with these agents. Adverse event reporting from postmarketing surveillance does not account for prescription volume and is often subjected to significant bias from confounding variables, quality of reported data, duplication, and underreporting of events.
| Serotonin receptor agonists
Serotonin (5-HT) is a monoamine neurotransmitter synthesized and stored primarily in the GI tract (~95%) and central nervous system (~5%). In the upper GI tract, serotonin activates 5-HT 4 receptors expressed in enteric neurons and smooth muscle cells. 69, 70 In turn, activated 5-HT 4 receptors facilitate acetylcholine release from myenteric neurons that enhance smooth muscle contractile activity and stimulate GI peristalsis. [71] [72] [73] [74] Cisapride, a non-selective 5-HT 4 receptor agonist which also functions as a 5-HT 2 and 5-HT 3 receptor antagonist, was approved initially by the FDA for treatment of nocturnal gastro-esophageal reflux in 1993. 75 However, evidence to support its use in other GI motility disorders was not robust enough to garner additional regulatory approvals.
Nevertheless, cisapride was used worldwide for on-label and off-label management of a wide range of GI motility disorders. Initial postmarketing surveillance data suggested that cisapride was both well tolerated and remarkably safe. [76] [77] [78] [79] Yet, by the mid-1990s, rare cases of exaggerated QTc response, TdP, and SCD began to emerge. 19, [80] [81] [82] Shortly thereafter, the cellular mechanism behind this pro-arrhythmic potential was linked to potent hERG/K v 11.1 blockade (Table 3 ) and subsequent risk of DI-LQTS. [83] [84] [85] Furthermore, as cisapride is primarily metabolized by CYP3A family members, marked elevations in plasma concentrations and associated QTc prolongation were observed with co-administration of CYP3A4 inhibitors (fluconazole, ritonavir, grapefruit juice, etc.).
86,87
Similar to domperidone and erythromycin, the vast majority of cisapride-associated TdP and SCD occurred with CYP3A4 inhibitor coadministration and/or in individuals with ≥1 patient-specific DI-LQTS risk factor (Table 1) . Despite an initial FDA "black box" warning in 1995 and subsequent expansions in 1996 and 1998 warning of danger posed by the convergence of these patient-specific and drug-specific risk factors, cisapride was withdrawn voluntarily from the world market in 2000, largely due to the documentation of its ongoing inappropriate use. 88, 89 Tegaserod, a non-selective 5-HT 4 agonist and 5-HT 1 and 5-HT 2 receptor antagonist, received FDA approval for use in the treatment of women with constipation-predominant irritable bowel syndrome in 2002. 90, 91 Unlike cisapride, tegaserod displays weak affinity for hERG/ Kv11.1 in vitro, 90, 92 is not extensively metabolized by CYP3A family members, 93 and does not cause an exaggerated QTc response or increased risk of TdP (Table 3) . 94 However, in comparison to placebo, tegaserod was associated with a nearly 10-fold (0.01% vs 0.1%) increase in the rate atherosclerotic cardiovascular disease (ASCVD)-related adverse events, such as myocardial infarction, unstable angina, and stroke. 91 Despite a lack of evidence for causality, definitive pathophysiologic mechanism(s), and a subsequent matched case-control study that found no association between tegaserod and ASCVD-related ad- 
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Although postmarketing surveillance data are currently limited or unavailable and the effect on cardiovascular PI3K signaling is unknown, these "second-generation" 5-HT 4 receptor agonists display greater 5-HT 4 selectivity, minimal affinity for hERG/K v 11.1 K+ channels, and substantially reduced DI-LQTS/TdP/SCD liability in comparison to their predecessors (Table 3) . [96] [97] [98] [99] Thus, 5-HT 4 receptor agonists such as prucalopride and velusetrag show great promise, both from the GI motility therapeutic efficacy and cardiovascular safety perspectives.
| Ghrelin receptor agonists
Ghrelin is a motilin-related peptide released by endocrine cells in the stomach and, to a lesser extent, in the small intestine and colon. the FDA has granted a fast track review of relamorelin, and optimism surrounds the prospect that the first ghrelin receptor agonist could be approved for clinical use in the near future.
| Mitigating the risk of DI-LQTS and DI-TdP associated with prokinetic agents
As illustrated in the sections above, many of the most efficacious In the following sections, we examine the roles that clinical decision support systems (CDSS) and precision genomic medicine may play in assisting healthcare providers to mitigate the small, but increased risk of DI-LQTS/TdP associated with those prokinetic agents in use today.
| Clinical decision support systems and DI-LQTS/TdP prevention
In the case of cisapride, the substantial contributions of patientspecific (ie, female sex, electrolyte abnormalities, structural heart disease, congenital LQTS, renal insufficiency, as summarized in Table 1) and drug-specific (ie, route of administration, co-administration of 
